{
    "nct_id": "NCT06453460",
    "official_title": "Prospective Evaluation of Efficacy of CMV-specific T Cell Immunity (CMV-TCIP) Directed Letermovir Prophylaxis After Allogeneic Hematopoietic Cell Transplantation",
    "inclusion_criteria": "* ≥ 18 years of age on the day of signing informed consent.\n* Karnofsky performance >70%\n* Have documented seropositivity for CMV (either donor or recipient CMV IgG seropositivity) before AHCT.\n* Eligible for AHCT from an HLA-matched related, matched unrelated, mismatched unrelated or haploidentical donor using either bone marrow or peripheral blood stem cells.\n* Have undetectable CMV DNA from a plasma sample collected within 5 days prior to enrollment.\n* Be within 28 days post-HSCT at the time of enrollment.\n* Be able to comply with medical recommendations or follow-up.\n* Has adequate organ functions determined by\n\n  1. Serum creatinine clearance ≥50 ml/min (calculated with Cockroft-Gault formula).\n  2. Bilirubin ≤1.5 mg/dl except for Gilbert's disease.\n  3. ALT or AST ≤200 IU/ml for adults.\n  4. Conjugated (direct) bilirubin < 2x upper limit of normal.\n  5. Left ventricular ejection fraction ≥40%.\n  6. Diffusing capacity for carbon monoxide (DLCO) ≥ 50% predicted corrected for hemoglobin.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a history of CMV end-organ disease or CS-CMVi within 6 months prior to enrollment.\n* Received within 7 days prior to screening or plans to receive during the study any of the following:\n\n  1. Ganciclovir\n  2. Valganciclovir\n  3. Foscarnet\n  4. Acyclovir (> 3200 mg PO per day or > 25 mg/kg IV per day)\n  5. Valacyclovir (> 3000 mg/day)\n  6. Famciclovir (> 1500 mg/day)\n* Received within 30 days prior to screening or plans to receive during the study any of the following drugs: cidofovir, CMV hyper-immune globulin, any investigational CMV antiviral agent/biologic therapy.\n* Has suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations.\n* Has an uncontrolled infection on the day of randomization.\n* Requires mechanical ventilation or is hemodynamically unstable at the time of randomization.",
    "miscellaneous_criteria": ""
}